Every milligram figure circulating in cannabis conversation came from somewhere, and the gap between its origin and the confidence with which it is repeated is the subject here.
1. Where the principle comes from
A maxim borrowed from geriatric prescribing
Start low, go slow was not invented for cannabis. It is an old rule from geriatric and psychiatric prescribing, used wherever a drug varies widely between individuals and the safe margin is narrow. The Minnesota Office of Cannabis Management’s 2023 dosing report found nearly every guideline it reviewed converging on it.
Why cannabis strains the rule harder than most drug classes
A preparation is a mixture, not a single molecule; there is no validated blood level to titrate against; absorption differs by route; and the curve is not reliably linear. The same report notes most studies are small and low quality, and that in Wang and colleagues (2021) no trial followed patients beyond 5.5 months.
2. The dose bands reported in the literature
None of the clinical consensus documents reviewed for this article define the four bands circulating online — microdose, low, standard, high. That language comes from dispensary blogs and wellness pages, which is why the figures shift from page to page.
| Informal band | Daily tetrahydrocannabinol figure | Comparable published figure |
|---|---|---|
| Microdose | Below about 2.5 mg | Almog and colleagues (European Journal of Pain, 2020) tested inhaled doses of 0.5 mg and 1.0 mg in 27 pain patients |
| Low | About 2.5–10 mg | MacCallum and Russo (European Journal of Internal Medicine, 2018): oral start of 2.5 mg, or 1.25 mg if elderly |
| Standard | About 10–30 mg | Bell and colleagues (Cannabis and Cannabinoid Research, 2023): 10–15 mg daily divided, in multiple sclerosis trials |
| High | Above about 30 mg | MacCallum and Russo (2018): above 20–30 mg daily may raise adverse events without improving efficacy |
Cannabidiol is looser still: MacCallum and Russo give oral starting doses of 5–20 mg per day divided, alongside research maxima of 800 mg in psychosis studies and 2,500 mg in seizure research. The Minnesota report puts the practical ceiling “as high as 800 mg/day, but typically much closer to 50–100 mg/day.” All of these are literature figures rather than personal thresholds.
3. Titration schedules in consensus guidance
Three published protocols side by side
These come from a modified Delphi consensus by Bhaskar and colleagues (Journal of Cannabis Research, 2021) and from MacCallum and colleagues (Frontiers in Pharmacology, 2021).
| Protocol | Starting figure | Increment and interval | Ceiling |
|---|---|---|---|
| Bhaskar, conservative | 5 mg cannabidiol daily | 5–10 mg cannabidiol every 2–3 days; tetrahydrocannabinol from 1 mg, +1 mg weekly | 40 mg/day each |
| Bhaskar, routine | 5 mg cannabidiol twice daily | 10 mg/day cannabidiol every 2–3 days; tetrahydrocannabinol from 2.5 mg, +2.5 mg every 2–7 days | 40 mg/day each |
| Bhaskar, rapid | 2.5–5 mg of each, once or twice daily | 2.5–5 mg/day of each every 2–3 days | 40 mg/day tetrahydrocannabinol |
| MacCallum and Russo 2018, oral | 2.5 mg at bedtime; 1.25 mg if elderly | 1.25–2.5 mg every 2 days | 20–30 mg/day |
| MacCallum 2021, chronic pain | 5–10 mg cannabidiol daily; 2.5 mg tetrahydrocannabinol evening, 1–1.25 mg if elderly | +1–2.5 mg tetrahydrocannabinol every 2–3 days; +5–10 mg cannabidiol every 1–2 days | 30 mg/day tetrahydrocannabinol |
For inhaled routes MacCallum and Russo describe one inhalation, a 15-minute wait, then one more every 15–30 minutes until symptom control.
How long a trial runs before it is called a failure
MacCallum and colleagues (2021) describe review at 2–4 week intervals, define response as roughly a 30% fall in pain intensity or a gain in function, and call a trial unsuccessful once 30 mg or more of tetrahydrocannabinol daily is reached without adequate response, with discontinuation by taper of 2.5–5 mg every 2–3 days. Bell and colleagues (2023) rate this evidence moderate for pain, low for sleep and anxiety.
Where the guidance documents disagree
The daily tetrahydrocannabinol ceiling is 20–30 mg in MacCallum and Russo (2018), 30 mg in MacCallum (2021), 40 mg in Bhaskar (2021), and “somewhere between 20–40 mg/day” in the Minnesota report. Cannabidiol is capped at 40 mg/day by Bhaskar but is a minimum target of 50 mg daily in MacCallum 2021.
4. Choosing a ratio of tetrahydrocannabinol to cannabidiol
Why different symptom targets pull in different directions
Practice treats cannabidiol as the component introduced first and tetrahydrocannabinol as the one added second, more cautiously. Bell and colleagues (2023) describe cannabidiol in the daytime with tetrahydrocannabinol at bedtime, and a balanced product titrated to around 15 mg of each component in arthritis. Targets where daytime sedation is unwanted pull one way; night-time symptoms tolerate more tetrahydrocannabinol.
How thin the comparative evidence is
Very thin. The ratio charts shared online are dispensary and wellness publishing, not head-to-head trials. Published studies mostly compare a preparation against placebo, not one ratio against another at matched doses.
5. The biphasic dose-response
The anxiety case is the clearest
A biphasic dose-response means low and high doses of one substance produce opposite effects. In Childs, Lutz and de Wit (Drug and Alcohol Dependence, 2017), 42 volunteers received 7.5 mg tetrahydrocannabinol, 12.5 mg, or placebo before a psychosocial stress task. The 7.5 mg group reported less stress than placebo and recovered faster; the 12.5 mg group reported worse mood and appraised the task as more threatening. A 5 mg difference reversed the direction of effect.
A scoping review by Shustorovich and colleagues (Pain Medicine, 2024) screened 44 publications and synthesised 18. It reports the same inverted-U for cannabidiol in Linares and colleagues (2019), where only an intermediate dose affected anxiety while 150 mg and 600 mg did not, and Portenoy and colleagues (2012), where nabiximols at 1–4 sprays daily beat 11–16 sprays. It concludes that gaps here remain substantial.
What this does to the belief that more is better
If the curve turns over, someone raising the dose after an inadequate response may move further from benefit and read the worsening as evidence that still more is needed. Guidance treats an ineffective dose and an excessive one as opposite problems.
6. Why the same figure lands differently in two people
Route of administration
Radparvar (The Permanente Journal, 2024) reports inhaled onset at 0–10 minutes, duration 2–4 hours, bioavailability around 25% for combustion and 10–35% for vaporisation, against oral onset at 1–3 hours, duration 6–12 hours, bioavailability 4–12%.
Prior exposure and tolerance
Prior exposure is probably the largest single source of variation: a dose disabling for someone with no exposure history may be subclinical for a long-term daily user — the reason the Bhaskar rapid protocol exists for patients already on higher doses.
Body composition, genetics and age
Tetrahydrocannabinol is lipophilic and distributes into adipose tissue, affecting the slow terminal elimination seen in frequent users; Radparvar lists body fat percentage among the determinants of realised exposure. Sachse-Seeboth and colleagues (Clinical Pharmacology and Therapeutics, 2009), in 43 volunteers, found homozygous CYP2C9*3 carriers had a median oral tetrahydrocannabinol area-under-the-curve about three-fold higher than CYP2C9*1 homozygotes. Age adds susceptibility to sedation and falls — hence the reduced 1–1.25 mg starting figure in several protocols.
7. Tolerance and the tolerance break
What receptor imaging shows
Hirvonen and colleagues (Molecular Psychiatry, 2012) found cannabinoid type 1 receptor density about 20% lower in cortical regions of chronic daily cannabis smokers than controls; after roughly four weeks of monitored abstinence, density in the 14 participants completing follow-up had returned toward normal. D’Souza and colleagues (Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016), in 11 dependent men and 19 controls, found availability about 15% lower and the difference undetectable after two days.
Where popular advice outruns the evidence
Two days and four weeks are not the same answer, and neither was measured against symptom control in patients. The break durations circulating online — 48 hours, one week, 21 days, 28 days — are not clinical findings; they come from wellness publishing that borrowed the receptor language without the data. The imaging supports downregulation being real and reversible, not any particular break length.
8. The acute adverse reaction
What it looks like and what is done
Emergency medicine sources such as the Internet Book of Critical Care describe marked anxiety or panic, altered perception, impaired coordination and memory, sedation, and cardiovascular effects including tachycardia and, at higher exposures, bradycardia and hypotension. Management is largely supportive — a quiet room, minimal stimulation, time — with benzodiazepines for severe anxiety, and cannabis does not typically cause lethal toxicity alone. That is no reason for complacency: it records a four- to eight-fold rise in myocardial infarction risk after use, and a reaction in cardiac disease, in a driver, or in a child warrants urgent medical attention.
The delayed-onset trap with swallowed preparations
The United States Centers for Disease Control and Prevention states that edibles take 30 minutes to 2 hours to produce intoxicating effects, that effects can last longer than expected, and that because of the delay some people consume too much, leading to poisoning or serious injury; it adds that edible tetrahydrocannabinol content is often unknown or mislabelled. The trap: nothing happens, a second portion is taken, and both arrive together.
9. Cannabinoid hyperemesis syndrome
This under-recognised condition presents as recurrent, stereotyped episodes of severe nausea and vomiting in long-term, near-daily users, often with abdominal pain and compulsive hot bathing that briefly relieves symptoms. The Rome IV criteria require stereotypical vomiting resembling cyclic vomiting syndrome, prolonged prior use, and relief by sustained cessation.
Habboushe and colleagues (Basic and Clinical Pharmacology and Toxicology, 2018) found that among 155 hospital patients smoking on 20 or more days per month, 32.9% (95% confidence interval 25.5–40.3%) reported consistent symptoms. Cleveland Clinic patient information describes a hyperemetic phase of 24 to 48 hours and relief within about 10 days in most who stop. Cessation is the only documented resolution; topical capsaicin and low-dose haloperidol appear in emergency protocols on limited evidence.
10. Interactions to raise with a prescriber
Cannabinoids interact with the cytochrome P450 system, the liver’s main drug-metabolising machinery. Lopera, Amariles and Rodríguez (Journal of Clinical Medicine, 2022) report tetrahydrocannabinol inhibiting CYP1A2, CYP2B6, CYP2C9 and CYP2D6, and cannabidiol inhibiting CYP3A4, CYP2B6, CYP2C9, CYP2D6 and CYP2E1. Papaseit and colleagues (Pharmaceutics, 2025) add that both are highly protein-bound — a displacement risk with narrow-therapeutic-index drugs.
| Drug or class | What the literature reports | Why it matters |
|---|---|---|
| Warfarin | Lopera (2022) rated this pair highest risk, citing four case reports where the international normalised ratio rose to around 7.6 on average, with bleeding | Narrow index; needs monitoring |
| Clobazam | Papaseit (2025): metabolite N-desmethylclobazam rises three- to four-fold with cannabidiol, via CYP2C19 inhibition | Sedation and toxicity risk in epilepsy |
| Tacrolimus, everolimus | Cannabidiol raised tacrolimus peak concentration 4.2-fold and exposure 3.1-fold; everolimus about 2.5-fold | Very narrow margins |
| Sedatives, opioids, alcohol | Additive central nervous system depression; nervous-system drugs were 13 of 19 pairs in Lopera (2022) | Compounded sedation and fall risk |
| Other narrow-index drugs | Antiepileptics, antiarrhythmics, immunosuppressants and buprenorphine recur at medium-to-high concern | Level monitoring needs discussion |
A complete medication list, including over-the-counter products and supplements, belongs in front of the prescriber before cannabis is added.
11. The symptom diary
Titration protocols only work if there is a record to titrate against. Recall is unreliable; a diary turns impressions into data a clinician can act on at the reviews above.
| Field | What goes in it | Why the prescriber needs it |
|---|---|---|
| Date and time | Clock time of each administration | Shows timing patterns and coverage gaps |
| Product and route | As on the prescription | Route determines onset and duration |
| Amount taken | Measured amount, in prescription units | The only way an increment can be judged |
| Time to change | Minutes or hours until any effect | Separates a small dose from a slow route |
| Symptom score | Target symptom, 0–10, before and at peak | Response against a defined threshold |
| Sleep and function | Hours slept, awakenings, one activity managed or not | Often the first outcomes to shift; guidance treats function as a response criterion |
| Unwanted effects | Sedation, dizziness, palpitations, anxiety, nausea, with severity | The other half of the titration decision |
| Other medication, alcohol | Everything taken that day | Interactions are otherwise invisible |
Two habits make a diary useful: recording at the time rather than reconstructing at week’s end, and keeping the rating scale identical throughout. Bringing it to every appointment makes it a clinical instrument.
12. The Thai regulatory frame
The Ministerial Notification on Controlled Herbal Medicine (Cannabis) B.E. 2568, signed 23 June 2025 and effective 26 June 2025, designates cannabis flower a controlled herb and requires a medical prescription for supply and use, enforced from 1 July 2025. Prescriptions use an official template from the Department of Thai Traditional and Alternative Medicine and are capped at 30 days. Authorised prescribers include doctors, dentists, pharmacists and Thai traditional practitioners. Online and vending-machine sale is prohibited, as is advertising.
Self-titration outside this framework is not only unwise given the biphasic curve and the interaction profile — it sits outside the legal structure that makes lawful access possible. The prescriber sets preparation, ratio, route, starting figure and every adjustment.
13. What the evidence does not settle
Guidance documents disagree on ceilings, intervals and cannabidiol targets; no band boundary has an empirical basis; comparative ratio evidence is largely absent; receptor-recovery timelines differ by an order of magnitude. These figures are the best available starting points, but they are provisional, population-level, and a prescriber’s material rather than an instruction to a patient.
Members of the Asiannabis community are warmly invited to share how they track symptoms with their prescriber — which diary fields mattered, what got dropped as noise, and what turned a neglected log into one that changed a consultation.
This article is part of the Asiannabis Community educational series on medical cannabis. It is general information, not medical advice — treatment decisions belong with a licensed practitioner. Content is for educational purposes within jurisdictions where medical cannabis is legally permitted.